ArticleBMC complementary medicine and therapies2026
Immunostimulant activity of Centella asiatica (ECa 233) on RAW 264.7 macrophages.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe innate immune system serves as the body’s first line of defense, with macrophages playing a central role in pathogen recognition and elimination. Although Centella asiatica has long been used in traditional medicine, its immunostimulatory effects are not yet fully elucidated. This study investigated the immunostimulant activity of a standardized C. asiatica extract (ECa 233) on RAW 264.7 macrophages.
methodsECa 233 was first characterized using FT-IR and NMR spectroscopy. FT-IR identified key functional groups, while NMR provided detailed insights into molecular structure, together ensuring precise extract characterization for subsequent pharmacological evaluation. RAW 264.7 cells were treated with ECa 233 at concentrations of 1.5625–200 μg/mL. The production of nitric oxide (NO), hydrogen peroxide (H2O2), and reactive oxygen species (ROS) was assessed, along with macrophage functional activity using zymosan-NBT reduction and neutral red uptake assays. Inflammatory gene expression was analyzed via Reverse transcriptase polymerase chain reaction (RT-PCR).
resultsECa 233 significantly increased NO, H2O2, and ROS production without compromising cell viability and enhanced macrophage functional activity. RT-PCR results revealed upregulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), regulatory cytokines (TGF-β, IL-10, IL-12), surface markers (CXCR-1, CXCR-2), and inflammatory mediators (iNOS, COX-2).
conclusionThese findings suggest that ECa 233 activates macrophages and promotes immune responses, supporting its potential as an immunostimulant. Further in vivo studies are warranted to confirm its efficacy and therapeutic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.